European Archives - Page 1507 of 1573 - European Medical Journal

COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney…

Phase 3 trial of whole brain radiation therapy in addition to radiosurgery for brain metastases

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Andrew B. Lassman, MD, of Columbia University Medical Center, New York, NY…

The treatment landscape of metastatic kidney cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, provides an overview…

Phase 3 trial of eribulin versus dacarbazine in leiomyosarcoma and liposarcoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium…

Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results…

TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses…

Treatment of Secondary Mitral Regurgitation via Percutaneous Annuloplasty

Functional mitral regurgitation (FMR) is a common occurrence in patients with heart failure (HF). FMR is associated with as much as a 2-fold increase in…

EMJ Interventional Cardiology 3.1 2015

Welcome to this edition of European Medical Journal Interventional Cardiology, which we hope will provide you with a thorough analysis of some of the…

AndraTec Optimus & Optimus Covered XL Stents a Novel Technology Stent Device

In the daily practise of an interventional paediatric cardiologist we often miss adequate material to treat complex lesions in vessel stenosis.

Second-Line Cetuximab Active beyond Progression in Quadruple Wild-Type Patients with Metastatic Colorectal Cancer

BARCELONA-LUGANO, 4 July 2015 – Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes…